New Zealand Medsafe Medical Device Registration & WAND Notification Consulting
Navigate New Zealand's notification-based regulatory framework with confidence. NexorTest Technologies delivers end-to-end Medsafe WAND notification support, NZ sponsor services, and trans-Tasman market entry strategies for medical device manufacturers seeking access to the New Zealand healthcare market.
WAND Notification System
New Zealand operates a notification-based system through the WAND database managed by Medsafe, distinct from pre-market approval frameworks used in other jurisdictions.
Trans-Tasman Advantage
Leverage the TTMRA with Australia to streamline your NZ market entry using existing TGA registrations or CE Marking conformity evidence.
New Zealand Medical Device Consulting Services
Comprehensive Medsafe WAND notification and regulatory consulting services tailored to guide medical device manufacturers through every stage of New Zealand market access.
Medsafe WAND Notification
We manage the complete WAND notification process on your behalf, including device data compilation, GMDN coding, classification determination, and sponsor-level data entry into the Medsafe WAND database. Our team ensures your notification accurately reflects device specifications, intended use, and risk classification under the GHTF/IMDRF framework, minimizing the risk of Medsafe queries or audit flags that could delay your market timeline.
NZ Sponsor Services
New Zealand law mandates that every medical device supplied in the country has a local NZ-based sponsor. NexorTest connects manufacturers with established, compliant NZ sponsors or acts as your regulatory intermediary to fulfil sponsor obligations. We handle adverse event reporting pipelines, maintain statutory records, manage WAND listing updates, and ensure your sponsor arrangements satisfy the requirements of the Medicines Act 1981 and associated regulations throughout the product lifecycle.
CE/TGA Pathway Support
If your medical device already carries a CE Mark under the EU MDR or MDD, or is listed with Australia’s Therapeutic Goods Administration, we help you leverage that existing conformity evidence to accelerate WAND notification. Our consultants map your existing technical documentation, certificates, and declarations of conformity to the requirements expected by Medsafe, ensuring a streamlined notification that can achieve market entry in as few as one to three months.
Trans-Tasman Strategy
Maximize your Australasian market potential with an integrated Australia-New Zealand regulatory strategy. We leverage the Trans-Tasman Mutual Recognition Arrangement to create a unified filing approach, coordinating TGA registration in Australia with WAND notification in New Zealand. This dual-market strategy reduces documentation duplication, lowers total regulatory costs, and enables simultaneous or sequential market entry across both countries with a single coherent regulatory plan.
IVD Classification Support
In vitro diagnostic medical devices follow a separate four-tier classification system in New Zealand (IVD Class 1 through IVD Class 4). Our regulatory scientists evaluate your IVD product against the IMDRF classification rules, determine the appropriate risk class, identify conformity assessment requirements, and prepare the necessary documentation for WAND notification. We also advise on companion diagnostics, point-of-care testing devices, and self-testing IVDs that may require additional regulatory considerations.
Post-Market Compliance
Ongoing regulatory compliance in New Zealand extends beyond initial WAND notification. NexorTest supports your post-market surveillance programme, including adverse event and incident reporting to Medsafe, periodic safety update reports, field safety corrective actions, and WAND listing maintenance. We help you establish vigilance procedures that meet NZ requirements while aligning with your global post-market surveillance framework, ensuring uninterrupted market access throughout your device lifecycle.
New Zealand Medical Device Classification System
New Zealand follows the GHTF/IMDRF risk-based classification system. Understanding your device class is essential for determining the conformity evidence required for WAND notification.
| Device Class | Risk Level | Examples | Conformity Evidence |
|---|---|---|---|
| Class I | Low | Tongue depressors, examination gloves, reusable surgical instruments | Manufacturer self-declaration of conformity |
| Class I(m) | Low | Clinical thermometers, manual blood pressure monitors | Self-declaration plus measurement verification |
| Class I(s) | Low | Sterile wound dressings, sterile surgical drapes | Self-declaration plus sterilization validation |
| Class IIa | Medium | Hearing aids, powered surgical instruments, ultrasound probes | Notified Body or recognized conformity assessment |
| Class IIb | Medium-High | Ventilators, infusion pumps, bone fixation plates | Notified Body certificate or TGA conformity assessment |
| Class III | High | Coronary stents, hip prostheses, heart valves | Full Notified Body design and production audit |
| AIMD | Critical | Pacemakers, implantable defibrillators, cochlear implants | Full Notified Body assessment under AIMD directive or EU MDR |
| IVD Class 1 | Low | General laboratory reagents, specimen collection containers | Manufacturer self-declaration |
| IVD Class 2 | Medium | Pregnancy test kits, cholesterol self-testing, urine analysis strips | Conformity assessment with performance data review |
| IVD Class 3 | High | Blood glucose monitors, companion diagnostics, HLA typing | Notified Body or recognized body assessment |
| IVD Class 4 | Critical | HIV blood screening, Hepatitis B/C donor testing, blood grouping reagents | Full Notified Body assessment with batch verification |
How to Register Medical Devices in New Zealand
The Medsafe WAND notification process involves systematic preparation and compliance verification. Here is the step-by-step pathway NexorTest follows to bring your device to market in New Zealand.
Regulatory Gap Assessment
We begin by evaluating your existing regulatory documentation, including CE technical files, TGA submissions, ISO 13485 certificates, and ISO 14971 risk management files. This gap analysis identifies what additional documentation or data may be needed to satisfy Medsafe requirements and determines the most efficient pathway for WAND notification.
Device Classification
Using the GHTF/IMDRF classification rules adopted by New Zealand, we determine the correct risk classification for your device. This step considers the device’s intended purpose, duration of contact, invasiveness, energy source, and whether it incorporates medicinal substances or biological materials. Classification drives the level of conformity evidence required.
NZ Sponsor Appointment
We facilitate the appointment of a qualified NZ-based sponsor who will hold legal responsibility for your device in the New Zealand market. The sponsor agreement defines responsibilities for WAND management, adverse event reporting, record keeping, and regulatory correspondence with Medsafe.
Documentation Preparation
Our regulatory team compiles the notification dossier, including device descriptions, GMDN codes, classification justification, conformity assessment evidence (CE certificates or TGA listing), essential principles checklists, labeling compliance review, and instructions for use. All documentation is formatted to meet Medsafe expectations.
WAND Database Entry
The NZ sponsor submits the device notification through the WAND online system. Each device entry includes product identification details, sponsor information, classification data, conformity evidence references, and GMDN terminology. We perform quality checks on every data field before submission to ensure accuracy and completeness.
Listing Confirmation & Post-Market Setup
Once the WAND entry is confirmed, your device is legally notified for supply in New Zealand. We then establish your post-market surveillance framework, including adverse event monitoring protocols, periodic review schedules, and ongoing WAND listing maintenance to ensure continuous compliance as regulations evolve.
Why Choose NexorTest for NZ Medical Device Consulting
NexorTest Technologies combines deep Medsafe regulatory expertise with global medical device consulting experience to deliver efficient, reliable market access in New Zealand.
Medsafe-Specific Expertise
Our consultants possess in-depth knowledge of the Medicines Act 1981, the Medicines (Database of Medical Devices) Regulations 2003, and the WAND notification system. We stay current with Medsafe guidance updates, enforcement trends, and the evolving status of the Therapeutic Products Bill to provide advice grounded in the latest regulatory landscape.
Trans-Tasman Integration
We design unified Australia-New Zealand strategies that maximize the Trans-Tasman Mutual Recognition Arrangement. Manufacturers with existing TGA registrations benefit from our streamlined TTMRA pathway that reduces duplication and accelerates NZ market entry while maintaining full compliance on both sides of the Tasman.
Established NZ Sponsor Network
Finding a reliable NZ sponsor is a critical challenge for overseas manufacturers. NexorTest maintains partnerships with vetted, experienced NZ sponsors who understand their regulatory obligations and can provide long-term, dependable support for your WAND listing and post-market compliance requirements.
CE & TGA Pathway Acceleration
If your device already holds CE Marking or TGA listing, we leverage that existing conformity evidence to fast-track your WAND notification. Our mapping methodology aligns your existing technical documentation with Medsafe expectations, avoiding redundant testing and enabling market entry timelines of one to three months.
IVD & SaMD Specialization
New Zealand's growing focus on Software as a Medical Device and advanced IVDs requires specialized regulatory knowledge. Our team has deep experience with the IMDRF IVD classification framework, SaMD clinical evaluation methodologies, and the unique challenges these product categories present in the WAND notification context.
Regulatory Future-Proofing
With the Therapeutic Products Bill's uncertain status and ongoing EU MDR transition, the NZ regulatory landscape is evolving. NexorTest monitors legislative developments and advises manufacturers on preparedness strategies, ensuring your NZ market access remains uninterrupted regardless of how the regulatory framework changes in the coming years.
Frequently Asked Questions About NZ Medical Device Registration
Expert answers to the most common questions about Medsafe WAND notification, NZ sponsor requirements, and the regulatory pathway for medical devices in New Zealand.
How do I register a medical device in New Zealand?
New Zealand uses a notification-based system rather than a pre-market approval process. Medical devices must be listed on the WAND (Web Assisted Notification of Devices) database managed by Medsafe. You need to appoint an NZ-based sponsor, prepare device documentation including classification evidence and conformity assessment proof (typically CE Marking or TGA listing), and submit the WAND notification. Medsafe does not issue an approval certificate; instead, the device is listed on the WAND database, which serves as the official record of devices available in New Zealand. The governing legislation is the Medicines Act 1981 and the Medicines (Database of Medical Devices) Regulations 2003.
What is the WAND database and how does it work?
WAND stands for Web Assisted Notification of Devices. It is an online database managed by Medsafe where medical device sponsors must notify their devices before they can be legally supplied in New Zealand. Unlike approval-based systems such as the US FDA 510(k), WAND is a notification system, meaning the sponsor declares that the device meets applicable requirements and enters the relevant information into the database. Medsafe monitors the database and may audit entries, but devices are not individually reviewed before being listed. The sponsor is responsible for the accuracy of all information entered and must maintain the listing throughout the device’s market life.
Do I need a local sponsor to sell medical devices in New Zealand?
Yes, the Medicines Act 1981 and the Medicines (Database of Medical Devices) Regulations 2003 require that every medical device sold or distributed in New Zealand has an NZ-based sponsor. The sponsor is responsible for the WAND notification, maintaining device records, handling adverse event reporting, and ensuring ongoing compliance. Overseas manufacturers who do not have a local subsidiary must appoint an authorized NZ sponsor to fulfil these obligations. NexorTest can connect you with established NZ sponsors or help structure sponsor agreements that clearly define regulatory responsibilities and communication protocols.
Can I use my CE Mark or TGA listing to enter the New Zealand market?
Yes, New Zealand accepts CE Marking and TGA (Australian Therapeutic Goods Administration) listing as evidence of conformity for WAND notification. Under the Trans-Tasman Mutual Recognition Arrangement (TTMRA) between Australia and New Zealand, devices registered with the TGA in Australia can generally be supplied in New Zealand with a streamlined notification process. Similarly, CE-marked devices that meet European regulatory requirements are accepted as meeting NZ standards. This can significantly reduce the timeline for market entry to approximately one to three months, compared to six to eighteen months when building a regulatory dossier from scratch without existing conformity evidence.
How are medical devices classified in New Zealand?
New Zealand follows the GHTF/IMDRF classification framework, which aligns with the Global Harmonization Task Force model. Medical devices are classified into risk-based categories: Class I (lowest risk), Class I(m) (with measuring function), Class I(s) (supplied sterile), Class IIa, Class IIb, Class III (highest risk for general devices), and AIMD (Active Implantable Medical Devices). In vitro diagnostic devices follow a separate four-tier classification from IVD Class 1 through IVD Class 4. Classification determines the level of conformity evidence required for WAND notification and is based on factors including intended purpose, invasiveness, duration of use, and energy source.
What is the Therapeutic Products Bill and how will it affect NZ medical device regulation?
The Therapeutic Products Bill was proposed legislation intended to modernize New Zealand’s regulatory framework for medicines, medical devices, and other therapeutic products by replacing the Medicines Act 1981 with a more comprehensive regime. The bill would have introduced a pre-market approval system for higher-risk medical devices instead of the current notification-only approach. However, the bill’s status remains uncertain, and the current WAND notification system under the Medicines Act 1981 continues to govern medical device regulation. Manufacturers should monitor Medsafe announcements and work with regulatory consultants to prepare for potential changes while ensuring compliance with the existing system.
Ready to Enter the New Zealand Medical Device Market?
Partner with NexorTest Technologies for expert Medsafe WAND notification consulting, NZ sponsor services, and trans-Tasman regulatory strategy. Contact us today for a complimentary regulatory assessment.